From dimitris@3dp.com Fri Aug 18 08:03:54 1995 Received: from boris.3dp.com for dimitris@3dp.com by www.ccl.net (8.6.10/950810.1506) id IAA18820; Fri, 18 Aug 1995 08:01:12 -0400 Received: from europa.3dp.com by boris.3dp.com via SMTP (931110.SGI/930416.SGI) for chemistry@www.ccl.net id AA23077; Fri, 18 Aug 95 08:05:33 -0400 Received: by europa.3dp.com (931110.SGI) id AA13754; Fri, 18 Aug 95 08:02:46 -0400 From: "Dimitris Agrafiotis" Message-Id: <9508180802.ZM13752@europa.3dp.com> Date: Fri, 18 Aug 1995 08:02:45 -0400 X-Mailer: Z-Mail (3.1.0 22feb94 MediaMail) To: chemistry@www.ccl.net Subject: Re: Biosym/MSI merger Content-Type: text/plain; charset=us-ascii Mime-Version: 1.0 On Aug 17, 10:01pm, Keith Refson wrote: > The question that immediately sprang to my mind on reading about the > Biosym/MSI merger is "why?". What is the motivation for the two most > direct competitors in this field to combine? In plain english, it's called selection by elimination. 'Merger' is a synonym used by business executives. -- Dimitris K. Agrafiotis, PhD | e-mail: dimitris@3dp.com Principal Research Scientist | tel: (610) 458-6045 3-Dimensional Pharmaceuticals, Inc. | fax: (610) 458-8249 665 Stockton Drive, Suite 104 Exton, PA 19341